Article

University of Iowa launches Project 3000

Iowa City, IA-The University of Iowa is launching Project 3000 in an effort to identify all 3,000 U.S. men, women, and children who have Leber's congenital amaurosis (LCA).

Iowa City, IA-The University of Iowa is launching Project 3000 in an effort to identify all 3,000 U.S. men, women, and children who have Leber's congenital amaurosis (LCA).

To accomplish this, the project will offer genetic testing to identify individuals through its John and Marcia Carver Nonprofit Genetic Testing Laboratory. Philanthropic donations will reduce the cost of tests for families who lack health insurance.

LCA is an inherited form of blindness that becomes apparent shortly after birth. In recent years, it has been discovered that at least nine genes are known to cause about 65% of all cases. Project leaders say that research is so new that many individuals with the disorder are unaware that testing exists to identify the genes.

The project also aims to provide hope to individuals with the disorder and provide accurate information to families with the diagnosis. By collecting basic clinical information from those with LCA, doctors will be able to learn how each genetic subtype of LCA behaves over time to counsel patients better.

The project also aims to find cures by identifying patients with each genetic subtype so treatments may be tested as they become available. And project leaders hope to demonstrate to insurance companies the value in paying for genetic testing for LCA.

The research effort is being supported by the Center for Bioinformatics and Computational Biology, a joint research unit of the UI College of Engineering and Carver College of Medicine.

Chicago Cubs first baseman Derrek Lee and Boston Celtics chief executive officer and co-owner Wyc Grousbeck, both of whom have children with LCA, are involved in the project.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.